|
1
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR,
Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR
mutation in patients with non-small cell lung cancer: A systematic
review and meta-analysis. Oncotarget. 7:78985–78993. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massarelli E, Johnson FM, Erickson HS,
Wistuba II and Papadimitrakopoulou V: Uncommon epidermal growth
factor receptor mutations in non-small cell lung cancer and their
mechanisms of EGFR tyrosine kinase inhibitors sensitivity and
resistance. Lung Cancer. 80:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al FLAURA Investigators, : Osimertinib in
Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl
J Med. 378:113–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho BC, Chewaskulyong B, Lee KH,
Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T,
Okamoto I, Zhou C, et al: Osimertinib versus Standard of Care EGFR
TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC:
FLAURA Asian Subset. J Thorac Oncol. 14:99–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okamoto I, Morita S, Tashiro N, Imamura F,
Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K and Fukuoka M: Real
world treatment and outcomes in EGFR mutation-positive non-small
cell lung cancer: Long-term follow-up of a large patient cohort.
Lung Cancer. 117:14–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nature Medicine.
21:560–562. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
National Comprehensive Cancer Network
(NCCN), . NCCN Guidelines® Insights - Non-Small Cell
Lung Cancer, Version 5. 2018.
|
|
12
|
Wang S, Yan B, Zhang Y, Xu J, Qiao R, Dong
Y, Zhang B, Zhao Y, Zhang L, Qian J, et al: Different
characteristics and survival in non-small cell lung cancer patients
with primary and acquired EGFR T790M mutation. Int J Cancer.
144:2880–2886. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao J, Li HR, Jin C, Jiang JH and Ding JY:
Strategies to overcome acquired resistance to EGFR TKI in the
treatment of non-small cell lung cancer. Clin Transl Oncol.
21:1287–1301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niederst MJ, Hu H, Mulvey HE, Lockerman
EL, Garcia AR, Piotrowska Z, Sequist LV and Engelman JA: The
Allelic Context of the C797S Mutation Acquired upon Treatment with
Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent
Treatment Strategies Cancer Therapy. Clin Cancer Res. doi:
10.1158/1078-0432.CCR-15-0560.
|
|
16
|
Jia Y, Yun CH, Park E, Ercan D, Manuia M,
Juarez J, Xu C, Rhee K, Chen T, Zhang H, et al: Overcoming
EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 534:129–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uchibori K, Inase N, Araki M, Kamada M,
Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with
anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated
non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto H, Yatabe Y and Toyooka S:
Inherited lung cancer syndromes targeting never smokers. Transl
Lung Cancer Res. 7:498–504. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han B, Zhou X, Zhang RX, Zang WF, Chen ZY,
Song HD, Wan HY and Zheng CX: Mutations of the epidermal growth
factor receptor gene in NSCLC patients. Oncol Lett. 2:1233–1237.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C,
Wang J, Liu L, Wang Z, Ni J, et al: EGFR G796D mutation mediates
resistance to osimertinib. Oncotarget. 8:49671–49679. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Menon R, Müller J, Schneider P, Lakis S,
Thress K, Wolf J, Heukamp L, Heuckmann JM and Griesinger F: A novel
EGFR (C797) variant detected in a pleural biopsy specimen from an
osimertinib-treated patient using a comprehensive hy- brid
capture-based next-generation sequencing assay(J). J Thorac Oncol.
11:e105–e107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bersanelli M, Minari R, Bordi P, Gnetti L,
Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G,
Capelletto E, et al: L718Q mutation as new mechanism of acquired
resistance to AZD9291 in EG- FR- mutated NSCLC(J). J Thorac Oncol.
11:e121–e123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knebel FH, Bettoni F, Shimada AK, Cruz M,
Alessi JV, Negrão MV, Reis LFL, Katz A and Camargo AA: Sequential
liquid biopsies reveal dynamic alterations of EGFR driver mutations
and indicate EGFR amplification as a new mechanism of resistance to
osimertinib in NSCLC. Lung Cancer. 108:238–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y,
Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG,
et al: Amplification of EGFR T790M causes resistance to an
irreversible EGFR inhibitor. Oncogene. 29:2346–2356. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Li L, Han R, Jiao L, Zheng J and
He Y: Clinical analysis by next-generation sequencing for NSCLC
patients with MET amplification resistant to osimertinib. Lung
Cancer. 118:105–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ou SI, Agarwal N and Ali SM: High MET
amplification level as a resistance mechanism to osimertinib
(AZD9291) in a patient that symptomatically responded to crizotinib
treatment post-osimertinib progression. Lung Cancer. 98:59–61.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Planchard D, Loriot Y, André F, Gobert A,
Auger N, Lacroix L and Soria JC: EGFR-independent mechanisms of
acquired resistance to AZD9291 in EGFR T790M-positive NSCLC
patients. Ann Oncol. 26:2073–2078. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Li S, Hai J, Wang X, Chen T, Quinn
MM, Gao P, Zhang Y, Ji H, Cross DAE, et al: Targeting HER2
Aberrations in Non-Small Cell Lung Cancer with Osimertinib. Clin
Cancer Res. 24:2594–2604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oxnard GR, Thress K, Paweletz C, Stetson
D, Dougherty Lai BZ, Markovets A, Felip AE, Vivancos A, Kuang Y, et
al: ORAL17.07-Mechanisms of Acquired Resistance to AZD9291 in EGFR
T790M Positive Lung Cancer. Proceedings of the WCLC 2015 - 16th
World Conference on Lung Cancer (Denver, CO). 2015.
|
|
30
|
Chaft JE, Arcila ME, Paik PK, Lau C, Riely
GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, et al:
Coexistence of PIK3CA and other oncogene mutations in lung
adenocarcinoma-rationale for comprehensive mutation profiling. Mol
Cancer Ther. 11:485–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ludovini V, Bianconi F, Pistola L, Chiari
R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A,
Flacco A, et al: Phosphoinositide-3-kinase catalytic alpha and KRAS
mutations are important predictors of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors in
patients with advanced non-small cell lung cancer. J Thorac Oncol.
6:707–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ and
Yang JC: Acquired BRAF V600E Mutation as Resistant Mechanism after
Treatment with Osimertinib. J Thorac Oncol. 12:567–572. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Del Re M, Tiseo M, Bordi P, D'Incecco A,
Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, et
al: Contribution of KRAS mutations and c.2369C > T (p.T790M)
EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A
study on circulating tumor DNA. Oncotarget. 8:13611–13619. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eberlein CA, Stetson D, Markovets AA,
Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E,
Ross SJ, et al: Acquired Resistance to the Mutant-Selective EGFR
Inhibitor AZD9291 Is Associated with Increased Dependence on RAS
Signaling in Preclinical Models. Cancer Res. 75:2489–2500. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F,
Eschrich SA, Koomen JM and Haura EB: Phosphoproteomics Reveals MAPK
Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in
KRAS-Mutant Lung Cancer. Mol Cancer Res. 14:1019–1029. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piotrowska Z, Niederst MJ, Karlovich CA,
Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman
EL, Kalsy A, et al: Heterogeneity Underlies the Emergence of
EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive
Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov.
5:713–722. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirakawa H, Komiya K, Nakashima C, Ogusu
S, Nakamura T, Tanaka M, Takahashi K, Egashira Y, Kai K, Kimura S,
et al: A case of osimertinib-resistant lung adenocarcinoma
responded effectively to alternating therapy. Ann Transl Med.
6:4642018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Minari R, Bordi P, Del Re M, Facchinetti
F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C,
et al: Primary resistance to osimertinib due to SCLC
transformation: Issue of T790M determination on liquid re-biopsy.
Lung Cancer. 115:21–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li X, Wang S, Li B, Wang Z, Shang S, Shao
Y, Sun X and Wang L: BIM Deletion Polymorphism Confers Resistance
to Osimertinib in EGFR T790M Lung Cancer: A Case Report and
Literature Review. Target Oncol. 13:517–523. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tanimoto A, Takeuchi S, Arai S, Fukuda K,
Yamada T, Roca X, Ong ST and Yano S: Histone Deacetylase 3
Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib
Resistance in EGFR-Mutant Lung Cancer. Clin Cancer Res.
23:3139–3149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Iwama E, Sakai K, Azuma K, Harada D,
Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, et
al: Exploration of resistance mechanisms for epidermal growth
factor receptor-tyrosine kinase inhibitors based on plasma analysis
by digital polymerase chain reaction and next-generation
sequencing. Cancer Sci. 109:3921–3933. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Labbé C, Cabanero M, Korpanty GJ, Tomasini
P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, et
al: Prognostic and predictive effects of TP53 co-mutation in
patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung
Cancer. 111:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu
VW, Albacker L, Stephens PJ, Miller VA and Ali SM: Emergence of
novel and dominant acquired EGFR solvent-front mutations at Gly796
(G796S/R) together with C797S/R and L792F/H mutations in one EGFR
(L858R/T790M) NSCLC patient who progressed on osimertinib. Lung
Cancer. 108:228–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jang J, Son JB, To C, Bahcall M, Kim SY,
Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, et al: Discovery
of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem.
136:497–510. 2017. View Article : Google Scholar : PubMed/NCBI
|
